E 10 Psychedelic Substances And The 35 Companies Researching Them

This article identifies the 10 different psychedelic substances being studied by companies involved in clinical-stage research for the treatment of mental health conditions and the names of those companies doing research with each of those substances. [TM Editors Note: This article discusses several penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.]

Data Bridge Market Research forecasts that the global psychedelics market will grow from $2.1B in 2019 to $6.9B by 2027 which represents a 3.3 times increase in just 7 years. Below are the 10 psychedelic substances undergoing extensive research, those with the most therapeutic and commercial potential and the 35 companies that are involved in such research.

1. Ketamine

Ketamine, used primarily as an anesthetic in veterinary clinics, is the only psychedelic drug that is broadly legal today. Unfortunately, it has had the reputation of being used as a date rape or sexual assault drug (and referred to in those circles as Special K, Cat Valium or Kit Kat) as it can be slipped unnoticed into a drink causing the consumer to experience a loss of muscle function combined with only a dream-like awareness of what’s happening and not to being able to remember what happened the next day although they may have flashbacks of the event several weeks later.

The above being said, ketamine is now being used to treat chronic pain, alcohol withdrawal management, and depression despite its addictive properties, toxicity and unpleasant hallucinogenic properties.

The major public companies currently involved in ketamine-based clinical-stage research are Field Trip Health* (FTRPF), Seelos* (SEEL), Numinus* (LKYSF), Awakn Life* (AWKNF) and ATAI (ATAI). In addition, a couple of much smaller market cap companies are also involved in mental health research using ketamine, namely, PharmaTher (PHRRF) and Novamind Inc. (NVMDF) for a total of 7 companies.

*identifies companies that are constituents in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. You can see the performance of the index in this recent article: Which Psychedelic Drug Stock Category Outperformed This Past Week?

2. Psilocybin

Psilocybin, the primary psychoactive ingredients in “magic mushrooms”, is the most widely-researched psychedelic substance today due to its minimal toxicity, non-addictive nature and powerful medicinal effect of generating new neural pathways that allow different regions within the brain to communicate in new and more effective ways.

Psilocybin will likely become the first psychedelic drug to be de-scheduled by a major government and legalized for medicinal use. A recent poll in Canada shows that nearly 80% of the population favor legalizing psilocybin for medicinal use and, to that end, Health Canada has already been granting special exemptions to allow patients with critical healthcare needs to be treated with psilocybin-based therapies. In the U.S., however, while psilocybin enjoys rapidly increasing grassroots support at the local and even state level, psychedelics research remains blocked at the federal level. Legal use and commercialization of psilocybin may advance much faster in the EU and UK via their “real-world evidence” pathway to drug approval that advances drugs that are proven safe substances, a category into which psilocybin fits.

The major public companies involved in psilocybin research are Compass Pathways (CMPS), Cybin Inc.* (CLXPF), Mind Medicine (MNMD) and Mydecine* (MYCOF).

1 2 3 4
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.